These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25575721)

  • 21. Hormonal Contraception and Risk of Psychiatric and Other Noncommunicable Diseases in HIV-Infected Women.
    Castilho JL; Jenkins CA; Shepherd BE; Bebawy SS; Turner M; Sterling TR; Melekhin VV
    J Womens Health (Larchmt); 2015 Jun; 24(6):481-8. PubMed ID: 25751720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of exogenous hormones.
    McClelland RS
    J Acquir Immune Defic Syndr; 2005 Mar; 38 Suppl 1():S38-9. PubMed ID: 15867617
    [No Abstract]   [Full Text] [Related]  

  • 23. Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women.
    Richardson BA; Otieno PA; Mbori-Ngacha D; Overbaugh J; Farquhar C; John-Stewart GC
    AIDS; 2007 Mar; 21(6):749-53. PubMed ID: 17413696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anaphylaxis from medroxyprogesterone acetate.
    Selo-Ojeme DO; Tillisi A; Welch CC
    Obstet Gynecol; 2004 May; 103(5 Pt 2):1045-6. PubMed ID: 15121602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
    Renner RM; Edelman AB; Kaunitz AM
    Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda.
    Grabowski MK; Gray RH; Makumbi F; Kagaayi J; Redd AD; Kigozi G; Reynolds SJ; Nalugoda F; Lutalo T; Wawer MJ; Serwadda D; Quinn TC; Tobian AAR
    Lancet Glob Health; 2015 Aug; 3(8):e478-e486. PubMed ID: 26094162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations of hormonal contraceptive use with measures of HIV disease progression and antiretroviral therapy effectiveness.
    Whiteman MK; Jeng G; Samarina A; Akatova N; Martirosyan M; Kissin DM; Curtis KM; Marchbanks PA; Hillis SD; Mandel MG; Jamieson DJ
    Contraception; 2016 Jan; 93(1):17-24. PubMed ID: 26197261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retinal venous occlusion associated with depot medroxyprogesterone acetate.
    Deen BF; Shuler RK; Fekrat S
    Br J Ophthalmol; 2007 Sep; 91(9):1254. PubMed ID: 17709596
    [No Abstract]   [Full Text] [Related]  

  • 29. Accounting for anovulation and vaginal thinning during depot medroxyprogesterone acetate use.
    Atrio J
    J Infect Dis; 2015 Mar; 211(5):850. PubMed ID: 25217405
    [No Abstract]   [Full Text] [Related]  

  • 30. Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices.
    Birse KD; Romas LM; Guthrie BL; Nilsson P; Bosire R; Kiarie J; Farquhar C; Broliden K; Burgener AD
    J Infect Dis; 2017 Feb; 215(4):590-598. PubMed ID: 28011908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Fixed Drug Eruption to Medroxyprogesterone Acetate Injectable Suspension.
    Patel K; Cervantes JA; Keeling B; Adamson AS
    Cutis; 2022 Mar; 109(3):E12-E14. PubMed ID: 35659137
    [No Abstract]   [Full Text] [Related]  

  • 32. Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk.
    Schooling CM
    Lancet HIV; 2015 Sep; 2(9):e366. PubMed ID: 26423548
    [No Abstract]   [Full Text] [Related]  

  • 33. Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk.
    Seidman D; Averbach S; Smith-McCune K; Darney P
    Lancet HIV; 2015 Sep; 2(9):e365-6. PubMed ID: 26423545
    [No Abstract]   [Full Text] [Related]  

  • 34. Pigmented purpuric dermatosis as a delayed reaction to medroxyprogesterone acetate.
    Rose RF; Bishop R; Goulden V
    J Eur Acad Dermatol Venereol; 2008 Sep; 22(9):1150-1. PubMed ID: 18422540
    [No Abstract]   [Full Text] [Related]  

  • 35. Is medroxyprogesterone safe in women with long QT syndrome?
    Skinner JR; Vandenberg JI
    Heart Rhythm; 2012 Jul; 9(7):1148-9. PubMed ID: 22401936
    [No Abstract]   [Full Text] [Related]  

  • 36. Gynecology case challenge: vaginal bleeding in a woman taking an injectable contraceptive.
    Hill DA
    Medscape Womens Health; 1998 Jan; 3(1):4. PubMed ID: 9732093
    [No Abstract]   [Full Text] [Related]  

  • 37. Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss.
    Wooltorton E
    CMAJ; 2005 Mar; 172(6):746. PubMed ID: 15743913
    [No Abstract]   [Full Text] [Related]  

  • 38. 'Black box' warning added to contraceptive injection.
    FDA Consum; 2005; 39(2):3. PubMed ID: 16124078
    [No Abstract]   [Full Text] [Related]  

  • 39. New aspects of injectable contraception.
    Phillips OP
    Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombocytopenic purpura with depot medroxyprogesterone acetate and subsequent use of contraceptive implant: making decisions in the absence of evidence.
    Holman R; Stephen G
    J Fam Plann Reprod Health Care; 2005 Oct; 31(4):333-4. PubMed ID: 16274569
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.